Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
Alessandro D. Santin, Wei Deng, Michael Frumovitz, Natália Buza, Stefania Bellone, Warner K. Huh, Samir N. Khleif, Heather A. Lankes, Elena Ratner, Roisin E. O’Cearbhaill, Amir A. Jazaeri, Michael J. Birrer
Topics & Concepts
MedicineNivolumabCervical cancerOncologyPhase (matter)Internal medicineCancerImmunotherapyChemistryOrganic chemistryEndometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersColorectal and Anal Carcinomas